Evidence map›Paper›PMID 36806653›Full record

ArticleResuscitation2023

Preclinical evaluation of triiodothyronine nanoparticles as a novel therapeutic intervention for resuscitation from cardiac arrest.

Brian R Weil, Shannon E Allen, Thomas Barbaccia, Kimberly Wong, Abigail M Beaver, Elizabeth A Slabinski, Jeffrey G Mellott, Peter C Taylor Dickinson, Shaker A Mousa

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Resuscitation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Brian R WeilDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA. Electronic address: bweil@buffalo.edu.
Shannon E AllenDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA.
Thomas BarbacciaDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA.
Kimberly WongDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA.
Abigail M BeaverDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA.
Elizabeth A SlabinskiDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA.
Jeffrey G MellottDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA.
Peter C Taylor DickinsonDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA.
Shaker A MousaDepartment of Physiology & Biophysics, University at Buffalo, Buffalo, NY, USA; the Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, Albany, NY, USA; Department of Anatomy and Neurobiology, Northeast Ohio Medical University, Rootstown, OH, USA; Hematology Unit, Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt; Pro-Al Medico Technologies Inc., Suffern, NY, USA. Electronic address: shaker.mousa@acphs.edu.
University at Buffalo, State University of New York · US

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Immunomodulatory Therapy After Resuscitation From Cardiac ArrestR01HL160538 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Brian Raymond Weil · 2022 to 2026
$2.3M
Amplification of Cardiosphere-Derived Cell TherapyF32HL114335 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI WEIL, BRIAN RAYMOND · 2013 to 2015
$159k
NCATS NIH HHS UL1 TR001412NHLBI NIH HHS F32 HL114335NHLBI NIH HHS R01 HL160538
6 · The paper itself

Abstract

backgroundGiven emerging evidence of rapid non-genomic cytoprotective effects of triiodothyronine (T3), we evaluated the resuscitative efficacy of two nanoparticle formulations of T3 (T3np) designed to prolong cell membrane receptor-mediated signaling.

methodsSwine (n = 40) were randomized to intravenous vehicle (empty np), EPI (0.015 mg/kg), T3np (0.125 mg/kg), or T3np loaded with phosphocreatine (T3np + PCr; 0.125 mg/kg) during CPR following 7-min cardiac arrest (n = 10/group). Hemodynamics and biomarkers of heart (cardiac troponin I; cTnI) and brain (neuron-specific enolase; NSE) injury were assessed for up to 4-hours post-ROSC, at which time the heart and brain were collected for post-mortem analysis.

resultsCompared with vehicle (4/10), the rate of ROSC was higher in swine receiving T3np (10/10; p < 0.01), T3np + PCr (8/10; p = 0.08) or EPI (10/10; p < 0.01) during CPR. Although time to ROSC and survival duration were comparable between groups, EPI was associated with a ∼2-fold higher post-ROSC concentration of cTnI vs T3np and T3np + PCr and the early post-ROSC rise in NSE and neuronal injury were attenuated in T3np-treated vs EPI-treated animals. Analysis of hippocampal ultrastructure revealed deterioration of mitochondrial integrity, reduced active zone length, and increased axonal vacuolization in EPI-treated animals vs controls. However, the frequency of these abnormalities was diminished in animals resuscitated with T3np.

conclusionsT3np achieved a ROSC rate and post-ROSC survival that was superior to vehicle and comparable to EPI. The attenuation of selected biomarkers of cardiac and neurologic injury at individual early post-ROSC timepoints in T3np-treated vs EPI-treated animals suggests that T3np administration during CPR may lead to more favorable outcomes in cardiac arrest.

Indexed as

Cardiopulmonary ResuscitationHeart ArrestAnimalsBiomarkersSwineThoraxTriiodothyronineBiomarkersTriiodothyronineCardiac ArrestIschemic InjuryNanoparticlesPhosphocreatineThyroid HormoneTriiodothyronine

Identifiers

PMID36806653
PMCPMC11154885
OpenAlexW4320883177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.